» Articles » PMID: 24448665

Isolation, Expansion and Characterization of Bone Marrow-derived Mesenchymal Stromal Cells in Serum-free Conditions

Overview
Journal Cell Tissue Res
Date 2014 Jan 23
PMID 24448665
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Bone marrow-derived mesenchymal stromal cells (BM-MSCs) heralded a new beginning for regenerative medicine and generated tremendous interest as the most promising source for therapeutic application. Most cell therapies require stringent regulatory compliance and prefer the use of serum-free media (SFM) or xeno-free media (XFM) for the MSC production process, starting from the isolation onwards. Here, we report on serum-free isolation and expansion of MSCs and compare them with cells grown in conventional fetal bovine serum (FBS)-containing media as a control. The isolation, proliferation and morphology analysis demonstrated significant differences between MSCs cultured in various SFM/XFM in addition to their difference with FBS controls. BD Mosaic™ Mesenchymal Stem Cell Serum-Free media (BD-SFM) and Mesencult-XF (MSX) supported the isolation, sequential passaging, tri-lineage differentiation potential and acceptable surface marker expression profile of BM-MSCs. Further, MSCs cultured in SFM showed higher immune suppression and hypo-immunogenicity properties, making them an ideal candidate for allogeneic cell therapy. Although cells cultured in control media have a significantly higher proliferation rate, BM-MSCs cultured in BD-SFM or MSX media are the preferred choice to meet regulatory requirements as they do not contain bovine serum. While BM-MSCs cultured in BD-SFM and MSX media adhered to all MSC characteristics, in the case of few parameters, the performance of cells cultured in BD-SFM was superior to that of MSX media. Pre-clinical safety and efficiency studies are required before qualifying SFM or XFM media-derived MSCs for therapeutic applications.

Citing Articles

High throughput morphological screening identifies chemically defined media for mesenchymal stromal cells that enhances proliferation and supports maintenance of immunomodulatory function.

Spoerer T, Larey A, Asigri W, Daga K, Marklein R Stem Cell Res Ther. 2025; 16(1):125.

PMID: 40055728 PMC: 11889916. DOI: 10.1186/s13287-025-04206-8.


Animal origins free products in cell culture media: a new frontier.

Golshan M, Dortaj H, Rajabi M, Omidi Z, Golshan M, Pourentezari M Cytotechnology. 2024; 77(1):12.

PMID: 39654546 PMC: 11625046. DOI: 10.1007/s10616-024-00666-7.


Comparative Analysis of Serum and Serum-Free Medium Cultured Mesenchymal Stromal Cells for Cartilage Repair.

Kang M, Yang Y, Zhang H, Zhang Y, Wu Y, Denslin V Int J Mol Sci. 2024; 25(19).

PMID: 39408956 PMC: 11476526. DOI: 10.3390/ijms251910627.


Clinical and preclinical studies of mesenchymal stem cells to alleviate peritoneal fibrosis.

Zheng L, Chen W, Yao K, Xie Y, Liao C, Zhou T Stem Cell Res Ther. 2024; 15(1):237.

PMID: 39080683 PMC: 11290310. DOI: 10.1186/s13287-024-03849-3.


Regulation of self-renewal and senescence in primitive mesenchymal stem cells by Wnt and TGFβ signaling.

Mazzella M, Walker K, Cormier C, Kapanowski M, Ishmakej A, Saifee A Stem Cell Res Ther. 2023; 14(1):305.

PMID: 37880755 PMC: 10601332. DOI: 10.1186/s13287-023-03533-y.